PharmiWeb.com - Global Pharma News & Resources

General - Press Releases

Date Title Company
03-Mar-2021 Global Healthtech Innovator NuroKor Accelerates US Expansion With Major New 5 Year Medi-Launch Partners Partnership and International Investment Businesswire
03-Mar-2021 Global Medical Foams Market Trajectory & Analytics Report 2020-2027 with Short-term Impacts of COVID-19 on Production & Procurement - ResearchAndMarkets.com Businesswire
03-Mar-2021 4D Pharma to Present at Upcoming Investor Conferences in March Businesswire
03-Mar-2021 Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome Businesswire
03-Mar-2021 Azura Ophthalmics Announces Positive Topline Results From Phase 2 Program of the Company’s Investigational Treatment for Meibomian Gland Dysfunction Businesswire
03-Mar-2021 Exicure Granted Orphan Drug Designation by the U.S. Food and Drug Administration for Cavrotolimod Businesswire
03-Mar-2021 SQZ Biotech to Present at H.C. Wainwright Global Life Sciences Conference Businesswire
03-Mar-2021 Merck to Present New Data from Various HIV Research and Development Programs at CROI 2021 Businesswire
03-Mar-2021 Merck to Present at the Barclays Global Healthcare Conference Businesswire
03-Mar-2021 Cybin Inc. Announces Uplisting to OTCQB Venture Market Businesswire
03-Mar-2021 Asia Pacific Medical Writing Market Forecast to 2027: Leading Players are Cactus Communications, Certara, and Covance - ResearchAndMarkets.com Businesswire
03-Mar-2021 Two Day Online Medical Device Regulation Seminar: Lead Auditor EN ISO 13485:2016 and EU MDR 2017/745 - March 8-9, 2021 - ResearchAndMarkets.com Businesswire
03-Mar-2021 EU & UK Conclude Decentralised Procedure Approval for Bijuva® (Estradiol & Progesterone) Capsules for Hormone Replacement Therapy Businesswire
03-Mar-2021 UK Regulatory Announcement: Net Asset Value(s) Businesswire
03-Mar-2021 Nordic Bioscience Welcomes Investment from KKR for Next Phase of Growth Businesswire
03-Mar-2021 Vifor Pharma schliesst 2020 mit starkem Geschäftsergebnis und EBITDA-Anstieg um über 29% auf 576 Millionen Schweizer Franken ab1 Businesswire
03-Mar-2021 Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth1 Businesswire
03-Mar-2021 Vifor Pharma affiche de solides résultats pour l’année 2020 avec un EBITDA de CHF 576 mio., en croissance de plus de 29%1 Businesswire
03-Mar-2021 ERS Genomics Licenses CRISPR Gene Editing Technology to Otsuka Pharmaceutical Businesswire
02-Mar-2021 WestPark Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) Businesswire